Tags: theranos | 9 billion | startup | bad | blood

Theranos: The Extraordinary Rise and Fall of a $9 Billion Startup

Theranos: The Extraordinary Rise and Fall of a $9 Billion Startup

Health technology entrepreneur and the youngest self-made female billionaire Elizabeth Holmes. The company she founded, Theranos, claimed fraudulently that it had devised a revolutionary blood-testing technology to detect a number of diseases. The SEC. fined her $500,000 forced her to step sown as head of Theranos and surrender $19 million in stocks. © Laurence Agron | Dreamstime.com

By Friday, 21 December 2018 09:58 AM Current | Bio | Archive

Looking for a book that reads like a thriller yet provides insights into a number of topical market and investment issues? How about a narrative that is exciting because of — rather than despite — an ending that is known to most readers well before they pick up the book? Or a cautionary lesson about startups, unicorns, venture capital and high-brow boards?

If you have answered yes to any of these questions, then “Bad Blood: Secrets and Lies in a Silicon Valley Startup” is for you. This extraordinarily engaging tale by the Wall Street Journal reporter John Carreyrou is my pick for most interesting read of 2018. It has accumulated accolades, including this year’s award for the Financial Times and McKinsey Business Book of the Year. (Full disclosure: I have served on the jury for this award since 2014.)

'Bad Blood' describes the extraordinary rise and fall of Theranos and Elizabeth Holmes, its founder and chief executive officer. The blood-testing startup grew to be valued at about $9 billion only to collapse after its top executives were accused of fraud. The book shows how misguided determination and deception consumed venture capital and tarnished the reputations of those who wanted to believe in an inspirational mission and business venture, yet should have known better.

The insights go well beyond how startups, founders and their backers can get carried away by their ability to create, embrace and disseminate misrepresentations. In the case of Theranos, conviction and the will to succeed that were important drivers of success became guarantees of failure and mind-blowing deception.

The tale also demonstrates what happens when venture capital and public personalities desperately want to back a mission, concept or person. Carreyrou’s brilliant reporting identifies multiple internal and external failures that, at their root, reflected an over-eagerness to embrace what seemed to be a noble, innovative and principled initiative, so much so that careful due diligence and basic fiduciary duties gave way to blind hope.

There was a time when Holmes, and her ambition to provide us with greater ease and control over basic medical procedures and records, was inspirational and would command standing ovations. Then, she was perceived to be helping us feel more empowered about our health care. Those worthy ambitions have now collapsed, leaving a once-unimaginable series of failures and shams. Carreyrou unveiled a story for the ages. Through masterful writing and reporting he reminds us that a principled mission, backed by the establishment elites and admired venture capital, is far from sufficient to ensure success.

Mohamed A. El-Erian is a Bloomberg Opinion columnist. He is the chief economic adviser at Allianz SE, the parent company of Pimco, where he served as CEO and co-CIO. His books include “The Only Game in Town” and “When Markets Collide.”

© Copyright 2020 Bloomberg L.P. All Rights Reserved.

1Like our page
“Bad Blood” chronicles the journey of a medical startup that grew to be valued at about $9 billion only to collapse in disgrace.
theranos, 9 billion, startup, bad, blood
Friday, 21 December 2018 09:58 AM
Newsmax Media, Inc.
Newsmax TV Live

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved